146O - Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)

Date 07 October 2016
Event ESMO 2016 Congress
Session Breast cancer, early
Topics Breast Cancer, Early Stage
Presenter Steven Shak
Citation Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364
Authors S. Shak1, D.P. Miller2, N. Howlader3, N. Gliner2, W. Howe4, N. Schussler4, K. Cronin3, F.L. Baehner2, L. Penberthy3, V.I. Petkov3
  • 1Translational Sciences, Genomic Health, Inc., 94063 - Redwood City/US
  • 2Translational Sciences, Genomic Health, Inc., Redwood City/US
  • 3Division Of Cancer Control And Population Sciences, National Cancer Institute, Rockville/US
  • 4Analytic Services & Data Management, Information Management Systems, Inc., Calverton/US

Abstract

Background

BC diagnoses in older patients (pts) are rising as population demographics change and life expectancy increases. The multinational TEAM study (N = 9,766) reported worse outcomes for older pts with HR+ BC (JAMA. 2012;307:590). To confirm this finding and to examine the role of tumor biology, SEER and Genomic Health collaborated to electronically supplement SEER registries with RS results and evaluate BC-specific mortality (BCSM).

Methods

21-gene RS results were provided to the NCI-sponsored SEER registries and linked to SEER BC cases. Eligible pts were diagnosed (Jan 2004 – Dec 2011) with N0 HR+ BC, and had no prior malignancy or multiple tumors. BCSM, defined previously (JNCI. 2010;102:1584), was analyzed separately for pts

Results

Of 184,190 eligible pts, 70%/30% were  1-2 cm). Reported chemotherapy (CT) use and 5-y BCSM are shown in Table. CT use was lower for pts ≥70 y (p 

Conclusions

This large population-based observational study of N0 HR+ BC shows that unacceptably high BCSM persists in US clinical practice for pts ≥70 y with either no 21-gene assay done or an RS ≥18 (but not RS

Clinical trial identification

N/A

Legal entity responsible for the study

Steven Shak, Dave P. Miller, Lynne Penberthy, Valentina I. Petkov

Funding

National Cancer Institute

Disclosure

S. Shak, D.P. Miller, N. Gliner, F.L. Baehner: Employed by Genomic Health; stock ownership in Genomic Health. All other authors have declared no conflicts of interest.